Treatment of recurrent malignant gliomas with fotemustine monotherapy: Impact of dose and correlation with MGMT promoter methylation

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Fabi, Alessandra ^a   Metro, Giulio ^a   Russillo, Michelangelo ^a   Vidiri, Antonello ^a   Carapella, Maria Carmine ^a   Maschio, Marta ^a   Cognetti, Francesco ^a   Jandolo, Bruno ^a   Mirri, Maria ^a   Sperduti, Isabella ^a   Telera, Stefano ^a   Carosi, Mariantonia ^a   Pace, Andrea ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FOTEMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ANTINEOPLASTIC AGENT; NITROSOUREA DERIVATIVE; ORGANOPHOSPHORUS COMPOUND;

ADULT; AGED; ANEMIA; ARTICLE; ASTROCYTOMA; CANCER CONTROL; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PATIENT SELECTION; PROMOTER REGION; THROMBOCYTOPENIA; TUMOR RECURRENCE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; FOLLOW UP; GENETICS; GLIOMA; KARNOFSKY PERFORMANCE STATUS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NAUSEA; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; GLIOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NAUSEA; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; NITROSOUREA COMPOUNDS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; ORGANOPHOSPHORUS COMPOUNDS; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 65349095669     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-101     Document Type: Article

References (27)

1. De Vita VT Hellman S Rosenberg SA Cancer: Principles & practice of oncology Philadelphia: Lippincott Williams & Wilkins 8, 2008.
2. Stewart LA Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials Lancet 2002, 359:1011-1018. 10.1016/S0140-6736(02)08091-1 11937180
3. Wen PY Kesari S Malignant gliomas in adults N Engl J Med 2008, 359:492-507. 10.1056/NEJMra0708126 18669428
4. Hayes MT Bartley J Parsons PG Eaglesham GK Prakash AS Mechanism of action of fotemustine, a new chloroethylnitrosourea anticancer agent: evidence for the formation of two DNA-reactive intermediates contributing to cytotoxicity Biochemistry 1997, 36:10646-10654. 10.1021/ bi970791q 9271495
5. Levin VA Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability Med Chem 1980, 23:682-684. 10.1021/jm00180a022
6. Meulemans A Giroux B Hannoun P Robine D Henzel D Comparative diffusion study of two nitrosoureas: Carmustine and fotemustine in normal rat brain, human and rat brain biopsies Chemotherapy 1991, 37:86-92. 2032474
7. Malhaire JP Lucas B Simon H Person H Dam-Hieu P Labat JP Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas Bull Cancer 1999, 86:289-294. 10210763
8. Frenay M Giroux B Khoury S Derlon JM Namer M Phase II study of fotemustine in recurrent supratentorial malignant gliomas Eur J Cancer 1991, 27:852-856. 1834116
9. Trevisan E Laguzzi E Ruda R Guarneri D Soffietti R Safety and efficacy of fotemustine in recurrent or progressive gliomas [abstract] J Neurol 2008, 255:s93. 10.1007/s00415-008-6017-7
10. Esteller M Herman JG Generating mutations but providing chemosensitivity: The role of O6-methylguanine DNA methyltransferase in human cancer Oncogene 2004, 23:1-8. 10.1038/sj.onc.1207316 14712205
11. Kaina B Mühlhausen U Piee-Staffa A Christmann M Garcia Boy R Rösch F Schirrmacher R Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: Comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death J Pharmacol Exp Ther 2004, 311:585-593. 10.1124/jpet.104.071316 15254145
12. Kaina B Christmann M Naumann S Roos WP MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents DNA Repair (Amst) 2007, 6:1079-1099. 10.1016/ j.dnarep.2007.03.008 17485253
13. Hegi ME Diserens AC Gorlia T Hamou MF de Tribolet N Weller M Kros JM Hainfellner JA Mason W Mariani L Bromberg JE Hau P Mirimanoff RO Cairncross JG Janzer RC Stupp R MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 2005, 352:997-1003. 10.1056/ NEJMoa043331 15758010
14. Macdonald DR Cascino TL Schold SC Jr Cairncross JG Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 1990, 8:1277-1280. 2358840
15. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ ctc.htm
16. Kaplan EL Meier P Non parametric estimation from incomplete observations J Am Stat Assoc 1958, 53:457-481. 10.2307/2281868
17. Cox DR Regression models and life tables J Royal Stat Soc 1972, 4:187-200.
18. Kappelle AC Postma TJ Taphoorn MJ Groeneveld GJ Bent van den MJ van Groeningen CJ Zonnenberg BA Sneeuw KC Heimans JJ PCV chemotherapy for recurrent glioblastoma multiforme Neurology 2001, 56:118-120. 11148250
19. Rosenthal MA Ashley DL Cher L BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide J Clin Neurosci 2004, 11:374-375. 10.1016/j.jocn.2003.01.002 15080950
20. Brandes AA Tosoni A Basso U Reni M Valduga F Monfardini S Amistà P Nicolardi L Sotti G Ermani M Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) J Clin Oncol 2004, 22:4779-4786. 10.1200/JCO.2004.06.181 15570079
21. Stupp R Mason WP Bent van den MJ Weller M Fisher B Taphoorn MJ Belanger K Brandes AA Marosi C Bogdahn U Curschmann J Janzer RC Ludwin SK Gorlia T Allgeier A Lacombe D Cairncross JG Eisenhauer E Mirimanoff RO Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 2005, 352:987-996. 10.1056/NEJMoa043330 15758009
22. Scoccianti S Detti B Sardaro A Iannalfi A Meattini I Leonulli BG Borghesi S Martinelli F Bordi L Ammannati F Biti G Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: A single institution experience Anticancer Drugs 2008, 19:613-620. 10.1097/cad.0b013e3283005075 18525321
23. Filippeschi S Colombo T Bassani D De Francesco L Arioli P D'Incalci M Bartosek I Guaitani A Antitumor activity of the novel nitrosourea S10036 in rodent tumors Anticancer Res 1988, 8:1351-1354. 3064716
24. Filippini G Falcone C Boiardi A Broggi G Bruzzone MG Caldiroli D Farina R Farinotti M Fariselli L Finocchiaro G Giombini S Pollo B Savoiardo M Solero CL Valsecchi MG Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma Neuro Oncol 2008, 10:79-87. 2600841 17993634 10.1215/15228517-2007-038
25. Fazeny-Dörner B Veitl M Wenzel C Piribauer M Rössler K Dieckmann K Ungersböck K Marosi C Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme Anticancer Drugs 2003, 14:437-442. 10.1097/00001813-200307000-00008 12853885
26. Silvani A Lamperti E Gaviani P Eoli M Fiumani A Salmaggi A Falcone C Filippini G Botturi A Boiardi A Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients J Neurooncol 2008, 87:143-151. 10.1007/ s11060-007-9427-y 17576523
27. Parkinson JF Wheeler HR Clarkson A McKenzie CA Biggs MT Little NS Cook RJ Messina M Robinson BG McDonald KL Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma J Neurooncol 2008, 87:71-78. 10.1007/s11060-007-9486-0 18004504